NCT04179786View on ClinicalTrials.gov

A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™

PHASE4CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

November 1, 2015

Primary Completion Date

February 7, 2017

Study Completion Date

April 25, 2017

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Sci-B-Vac™

Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.

All Listed Sponsors
lead

VBI Vaccines Inc.

INDUSTRY

NCT04179786 - A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™ | Biotech Hunter | Biotech Hunter